Videos

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed JQ1 and other BET inhibitors he would like to study.

The hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Experts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.

The director of the Powell Gene Therapy Center at the University of Florida discussed gene therapy programs being conducted for Pompe disease.

The associate professor from the UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center discussed the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

The associate professor from The University of Texas MD Anderson Cancer Center discussed mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.

Eric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.

Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s future plans and research.

The professor and director of the Myeloma Center at the University of Arkansas for Medical Sciences discussed the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the 8,000 donated eye repository that aided his research in AMD.

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.

The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.

Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.

The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.

The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells.

The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.

Samarendra Mohanty, PhD, cofounder and president, Nanoscope Therapeutics, discussed the company’s technological platforms and RESTORE trial data.

Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.

The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.

Directors from the Moran Eye Center discussed their research on the genetics of age-related macular degeneration.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.

The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.